Published in Medical Letter on the CDC and FDA, June 13th, 2004
A first generic fluticasone cream to be approved by the FDA, Sandoz, Inc., a Novartis company, is marketing this new generic product.
On April 27, 2004, the company announced the tentative approval of the Abbreviated New Drug Application (ANDA). Atrix's product is the AB-rated generic to topical Cutivate (fluticasone propionate cream) cream 0.05%, which is marketed by GlaxoSmithKline PLC. Cutivate cream's patent expired May 14, 2004.
This product is typically...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA